BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia (PRNewswire) - Nov 17, 2023 - "BrainStorm Cell Therapeutics Inc...today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data. The presentation...will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm."
Biomarker • P3 data • Amyotrophic Lateral Sclerosis • CNS Disorders
|